During shortages of Wegovy, Ozempic, Mounjaro, and Zepbound, the FDA exercised temporary enforcement discretion , allowing compounding pharmacies to help meet patient demand. Once manufacturing stabilized: Semaglutide injection products were removed from the FDA Drug Shortage List Tirzepatide injection products were formally declared resolved Compounding reverted to pre-shortage federal and state limits Broad, shortage-based compounding is no longer allowed in 2026
When to Contact Your Healthcare Provider While mild nausea is expected, there are certain situations where you should seek professional guidance
But (and this is important): Medication is still just one piece of the puzzle
Never check it in luggage (cargo holds can freeze)
Lancet Diabetes Endocrinol 2024;12:162-173
Miyamoto Y, Akaike T, Maeda H